- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Enliven Therapeutics, Inc Q2 Loss Climbs | 1 | RTTNews | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Enliven Therapeutics GAAP EPS of -$0.49 beats by $0.04 | 1 | Seeking Alpha | ||
| 13.08. | Enliven Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.08. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | 200 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| 25.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | TD Cowen bekräftigt Kaufempfehlung für Enliven Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
| 20.06. | TD Cowen reiterates buy rating on Enliven Therapeutics stock | 1 | Investing.com | ||
| 16.06. | Goldman Sachs initiates Enliven Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics prices $200 million public offering | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering | 1 | Seeking Alpha | ||
| 13.06. | Enliven Therapeutics announces $200 million public offering | 5 | Investing.com | ||
| 13.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.06. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 330 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 30.05. | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | 1 | Investing.com Deutsch | ||
| 16.05. | BTIG raises Enliven Therapeutics stock target to $45 | 1 | Investing.com | ||
| 15.05. | Enliven Therapeutics GAAP EPS of -$0.57 beats by $0.01 | 1 | Seeking Alpha | ||
| 15.05. | Enliven Therapeutics stock target raised to $40 at H.C. Wainwright | 1 | Investing.com | ||
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 440 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
| 14.05. | Enliven reports positive Phase 1 trial data for ELVN-001 in CML | 1 | Investing.com | ||
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 455 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,738 | +0,30 % | Valneva korrigiert Finanzziele - Hoffnung bleibt auf Lyme-Impfstoff ab 2027 | Valneva hat eine neue Kreditfazilität über bis zu 500 Millionen US-Dollar mit von Pharmakon Advisors verwalteten Fonds abgeschlossen. Eine erste Tranche von 215 Millionen US-Dollar dient zur vollständigen... ► Artikel lesen | |
| BIOFRONTERA | 2,680 | -2,90 % | Benchmark reiterates Buy rating on Biofrontera stock amid tariff concerns | ||
| CRISPR THERAPEUTICS | 66,50 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| DENALI THERAPEUTICS | 13,355 | -0,89 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,255 | -2,41 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... ► Artikel lesen | |
| AGIOS | 36,400 | -1,09 % | Agios Pharmaceuticals, Inc.: Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia | First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on... ► Artikel lesen | |
| CELLECTIS | 3,750 | -1,70 % | Cellectis Inc.: Monthly information on share capital and company voting rights | ||
| VOYAGER THERAPEUTICS | 4,612 | +1,63 % | Voyager Therapeutics, Inc.: Voyager Reports Second Quarter 2025 Financial and Operating Results | - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise... ► Artikel lesen | |
| UNIQURE | 50,92 | -1,24 % | uniQure stock price target raised to $110 from $70 at H.C. Wainwright | ||
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 15,360 | 0,00 % | Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 | Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved... ► Artikel lesen | |
| SCILEX | 17,570 | 0,00 % | Scilex Holding Co - 8-K, Current Report | ||
| ALLOGENE THERAPEUTICS | 1,465 | 0,00 % | Allogene Therapeutics: Strategische Einblicke in Pipeline und Finanzlage | ||
| NUVATION BIO | 3,715 | 0,00 % | Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer | Sustained durability of responses demonstrated in both TRUST-I and TRUST-II with additional follow-up time TKI-naïve patients in TRUST-I achieved a median progression-free survival of 44.6 months... ► Artikel lesen |
ENLIVEN THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 20,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.